Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2019
Feb 25, 2019
7:00 AM EST
It has entered into a strategic alliance with ResearchDx to launch its Cchek™ Prostate Cancer Confirmation (Cchek™ PCC) test as a Laboratory Developed Test. ResearchDx is a CLIA certified, CAP Accredited laboratory located in Southern California.
Feb 21, 2019
7:00 AM EST
It has extended its collaboration with The Wistar Institute and Dmitry I. Gabrilovich , M.D., Ph.D. Gabrilovich is a pioneer in the field of myeloid-derived suppressor cell (MDSC) biology and its roles in cancer progression and therapy response.
Feb 13, 2019
7:00 AM EST
Dr. Amit Kumar , its President and CEO, will be presenting on a panel discussion at Moffitt Cancer Center's 13 th Annual Business of Biotech Conference being held on February 22, 2019 .
Jan 25, 2019
7:00 AM EST
It has made a recording of its January 24, 2019 conference call available on its website. The recording can be found on the Investor Presentation page of the company's website at www.anixa.com .
Jan 24, 2019
7:00 AM EST
The U.S. Patent and Trademark Office has issued a Notice of Allowance for the first patent covering Anixa subsidiary, Certainty Therapeutics, Inc.'s, CAR-T cancer treatment technology.
Jan 16, 2019
7:30 AM EST
It will hold a conference call on January 24, 2019 at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss its plan for 2019, including the commercialization path and timeline for Cchek™, its artificial intelligence based cancer diagnostic test, and the clinical path of its CAR-T based ovarian cancer therapeutic program.
2018
Dec 19, 2018
7:00 AM EST
It completed a Pre-Submission (Pre-Sub) meeting with the US FDA on December 17 , 2018.
Dec 03, 2018
7:00 AM EST
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek™, its artificial intelligence (AI) driven cancer detection technology, at the…
Nov 15, 2018
7:00 AM EST
It will present data from its ongoing studies in breast cancer utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology, at the AACR Special Conference on Tumor Immunology and Immunotherapy.
Nov 12, 2018
7:00 AM EST
Its two presentations at the 33 rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) are now available on its website at www.anixa.com . The presentations discuss the ongoing studies utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology.
Oct 29, 2018
7:00 AM EDT
It will present data from its ongoing studies utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology, at the 33 rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC).
Oct 24, 2018
7:00 AM EDT
A Pre-Submission (Pre-Sub) meeting with the US FDA has been scheduled on Monday, December 17 , 2018. The meeting is to discuss the proposed preclinical and clinical performance testing plan required to support a pre-market application, and to determine the appropriate regulatory pathway for the Cchek™ prostate cancer…
Oct 17, 2018
7:00 AM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on using the body's immune system to fight cancer, presented the results from its ongoing study utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology, at the 30th Anniversary AACR Special Conference –…
Oct 15, 2018
7:00 AM EDT
It has filed an IVD pre-submission with the US Food and Drug Administration (FDA) for use of its Cchek ™ artificial intelligence based cancer detection technology, as a prostate cancer test.
Oct 11, 2018
7:00 AM EDT
It has added to its Scientific Advisory Board, Jose Conejo-Garcia , MD PhD; Marco Davila , MD PhD; Linda Kelley , PhD; and Daniel Abate-Daga , PhD; the lead scientists from Moffitt Cancer Center developing a novel ovarian cancer CAR-T treatment.
Oct 05, 2018
7:00 AM EDT
It will present data from its ongoing studies utilizing Cchek™, Anixa's artificial intelligence (AI) driven early cancer detection technology, at the 30 th Anniversary AACR Special Conference – Convergence: Artificial Intelligence, Big Data and Prediction in Cancer.
